Russell Szmulewitz to Antineoplastic Agents
This is a "connection" page, showing publications Russell Szmulewitz has written about Antineoplastic Agents.
Connection Strength
1.110
-
SOX2 expression in prostate cancer drives resistance to nuclear hormone receptor signaling inhibition through the WEE1/CDK1 signaling axis. Cancer Lett. 2023 07 01; 565:216209.
Score: 0.375
-
Vemurafenib oral bioavailability: an insoluble problem. J Clin Pharmacol. 2014 Apr; 54(4):375-7.
Score: 0.199
-
Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer. Clin Cancer Res. 2023 01 04; 29(1):50-59.
Score: 0.091
-
Prevalence of potential interactions of medications, including herbs and supplements, before, during, and after chemotherapy in patients with breast and prostate cancer. Cancer. 2021 06 01; 127(11):1827-1835.
Score: 0.080
-
First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors. Clin Cancer Res. 2019 11 01; 25(21):6309-6319.
Score: 0.072
-
Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Invest New Drugs. 2018 10; 36(5):919-926.
Score: 0.067
-
Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer. Oncotarget. 2016 May 03; 7(18):26259-74.
Score: 0.058
-
Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study. Prostate. 2016 Feb 15; 76(3):286-93.
Score: 0.056
-
The pluripotency factor Nanog is directly upregulated by the androgen receptor in prostate cancer cells. Prostate. 2014 Nov; 74(15):1530-43.
Score: 0.051
-
A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study. Prostate Cancer Prostatic Dis. 2012 Mar; 15(1):87-92.
Score: 0.042
-
Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies. Clin Cancer Res. 2020 03 15; 26(6):1247-1257.
Score: 0.018